OppenheimerFunds Inc. trimmed its position in shares of LivaNova PLC (NASDAQ:LIVN) by 3.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,233,940 shares of the company’s stock after selling 45,887 shares during the period. OppenheimerFunds Inc.’s holdings in LivaNova were worth $152,971,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. PEAK6 Investments LLC acquired a new stake in LivaNova during the 3rd quarter valued at $4,441,000. Schwab Charles Investment Management Inc. grew its holdings in LivaNova by 4.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 286,372 shares of the company’s stock valued at $28,586,000 after purchasing an additional 12,517 shares in the last quarter. BlackRock Inc. grew its holdings in LivaNova by 6.1% during the 2nd quarter. BlackRock Inc. now owns 5,393,015 shares of the company’s stock valued at $538,332,000 after purchasing an additional 309,138 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in LivaNova during the 3rd quarter valued at $719,000. Finally, Cibc Bank USA acquired a new stake in LivaNova during the 3rd quarter valued at $227,000. 87.53% of the stock is owned by institutional investors and hedge funds.

Shares of LIVN stock opened at $96.56 on Thursday. The firm has a market cap of $4.79 billion, a price-to-earnings ratio of 29.17, a P/E/G ratio of 3.07 and a beta of 0.85. The company has a quick ratio of 1.21, a current ratio of 1.65 and a debt-to-equity ratio of 0.06. LivaNova PLC has a 1-year low of $76.14 and a 1-year high of $131.54.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, October 31st. The company reported $0.82 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.90 by ($0.08). The company had revenue of $272.10 million for the quarter, compared to analyst estimates of $275.03 million. LivaNova had a positive return on equity of 8.77% and a negative net margin of 8.31%. LivaNova’s revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.83 earnings per share. Equities analysts forecast that LivaNova PLC will post 3.1 earnings per share for the current fiscal year.

In other news, insider David S. Wise sold 1,500 shares of the firm’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $112.83, for a total value of $169,245.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $123.49, for a total transaction of $123,490.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,500 shares of company stock valued at $1,002,355. 0.41% of the stock is owned by company insiders.

LIVN has been the subject of several recent analyst reports. ValuEngine lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 28th. BidaskClub lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 22nd. Stifel Nicolaus raised their price objective on shares of LivaNova from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, September 17th. Jefferies Financial Group raised their price objective on shares of LivaNova to $150.00 and gave the stock a “buy” rating in a report on Tuesday, October 2nd. Finally, BTIG Research reissued a “hold” rating on shares of LivaNova in a report on Thursday, November 1st. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $122.20.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/12/06/livanova-plc-livn-position-trimmed-by-oppenheimerfunds-inc.html.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

Further Reading: Cash Flow

Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.